Polycystic Liver Disease: The Benefits of Targeting cAMP.
作者信息
Larusso Nicholas F, Masyuk Tatyana V, Hogan Marie C
机构信息
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.
出版信息
Clin Gastroenterol Hepatol. 2016 Jul;14(7):1031-4. doi: 10.1016/j.cgh.2016.03.008. Epub 2016 Mar 10.
Abstract
摘要
相似文献
1
Polycystic Liver Disease: The Benefits of Targeting cAMP.
Clin Gastroenterol Hepatol. 2016 Jul;14(7):1031-4. doi: 10.1016/j.cgh.2016.03.008. Epub 2016 Mar 10.
2
Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease.
J Hepatol. 2017 Mar;66(3):571-580. doi: 10.1016/j.jhep.2016.10.032. Epub 2016 Nov 5.
3
[Polycystic liver disease without autosomal dominant polycystic kidney disease].
Nefrologia. 2003 Sep-Oct;23(5):454-8.
4
Kidney and liver cysts in autosomal dominant polycystic kidney disease.
Nephrol Dial Transplant. 2010 Nov;25(11):3472-3. doi: 10.1093/ndt/gfq567. Epub 2010 Sep 15.
5
Fatal liver cyst rupture in polycystic liver disease complicated with autosomal dominant polycystic kidney disease: A case report.
Forensic Sci Int. 2016 May;262:e5-8. doi: 10.1016/j.forsciint.2016.03.045. Epub 2016 Mar 30.
6
Liver cysts in Congolese patients with autosomal dominant polycystic kidney disease follow a family pattern.
S Afr Med J. 2003 Jul;93(7):542-4.
7
Complex liver cysts in Autosomal Dominant Polycystic Kidney Disease.
Clin Imaging. 2017 Nov-Dec;46:98-101. doi: 10.1016/j.clinimag.2017.07.014. Epub 2017 Jul 25.
8
Effect of everolimus on polycystic liver volume in autosomal dominant polycystic kidney disease.
Clin Exp Nephrol. 2015 Aug;19(4):757-8. doi: 10.1007/s10157-014-1059-x. Epub 2014 Nov 26.
9
Weight loss in a patient with polycystic kidney disease: when liver cysts are no longer innocent bystanders.
Acta Clin Belg. 2015 Oct;70(5):369-71. doi: 10.1179/2295333715Y.0000000024. Epub 2015 Apr 12.
10
Liver cysts in patients with autosomal dominant polycystic kidney disease.
J Assoc Physicians India. 1993 Sep;41(9):590-1.
引用本文的文献
1
NAMPT Overexpression Drives Cell Growth in Polycystic Liver Disease through Mitochondrial Metabolism Regulation.
Am J Pathol. 2024 Aug;194(8):1528-1537. doi: 10.1016/j.ajpath.2024.04.010. Epub 2024 Jun 5.
2
Novel α-1,3-Glucosyltransferase Variants and Their Broad Clinical Polycystic Liver Disease Spectrum.
Genes (Basel). 2023 Aug 19;14(8):1652. doi: 10.3390/genes14081652.
3
Autophagy-mediated reduction of miR-345 contributes to hepatic cystogenesis in polycystic liver disease.
JHEP Rep. 2021 Aug 5;3(5):100345. doi: 10.1016/j.jhepr.2021.100345. eCollection 2021 Oct.
4
Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial.
Clin J Am Soc Nephrol. 2020 Sep 7;15(9):1267-1278. doi: 10.2215/CJN.13661119. Epub 2020 Aug 25.
5
Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.
Am J Pathol. 2018 Apr;188(4):981-994. doi: 10.1016/j.ajpath.2017.12.016. Epub 2018 Jan 31.
6
Pasireotide does not improve efficacy of aspiration sclerotherapy in patients with large hepatic cysts, a randomized controlled trial.
Eur Radiol. 2018 Jun;28(6):2682-2689. doi: 10.1007/s00330-017-5205-1. Epub 2018 Jan 9.
7
TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling.
Hepatology. 2017 Oct;66(4):1197-1218. doi: 10.1002/hep.29284. Epub 2017 Aug 26.
本文引用的文献
1
Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease.
Mayo Clin Proc. 2015 Aug;90(8):1030-7. doi: 10.1016/j.mayocp.2015.05.011. Epub 2015 Jul 9.
2
Lanreotide Reduces Liver Volume, But Might Not Improve Muscle Wasting or Weight Loss, in Patients With Symptomatic Polycystic Liver Disease.
Clin Gastroenterol Hepatol. 2015 Dec;13(13):2353-9.e1. doi: 10.1016/j.cgh.2015.05.039. Epub 2015 Jun 12.
3
Therapeutic Targets in Polycystic Liver Disease.
Curr Drug Targets. 2017;18(8):950-957. doi: 10.2174/1389450116666150427161743.
4
Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial.
J Hepatol. 2013 Jul;59(1):153-9. doi: 10.1016/j.jhep.2013.03.004. Epub 2013 Mar 14.
5
Diagnosis and management of polycystic liver disease.
Nat Rev Gastroenterol Hepatol. 2013 Feb;10(2):101-8. doi: 10.1038/nrgastro.2012.254. Epub 2013 Jan 8.
6
Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases.
Hepatology. 2013 Jul;58(1):409-21. doi: 10.1002/hep.26140. Epub 2013 Mar 6.
7
Somatostatin analog therapy for severe polycystic liver disease: results after 2 years.
Nephrol Dial Transplant. 2012 Sep;27(9):3532-9. doi: 10.1093/ndt/gfs152. Epub 2012 Jul 6.
8
The long-term outcome of patients with polycystic liver disease treated with lanreotide.
Aliment Pharmacol Ther. 2012 Jan;35(2):266-74. doi: 10.1111/j.1365-2036.2011.04923.x. Epub 2011 Nov 24.
9
Somatostatin analogues for treatment of polycystic liver disease.
Curr Opin Gastroenterol. 2011 May;27(3):294-300. doi: 10.1097/MOG.0b013e328343433f.
10
Octreotide reduces hepatic, renal and breast cystic volume in autosomal-dominant polycystic kidney disease.
Int Urol Nephrol. 2011 Jun;43(2):565-9. doi: 10.1007/s11255-010-9748-1. Epub 2010 May 7.
Zotero 插件